# Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)

> **NCT01140061** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 42 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** MK-0873 Patch
- **DRUG:** MK-0873 Cream
- **DRUG:** Placebo Patch
- **DRUG:** Placebo Cream
- **DRUG:** Plain patch

## Key facts

- **NCT ID:** NCT01140061
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-01
- **Primary completion:** 2011-03-01
- **Final completion:** 2011-03-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01140061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01140061, "Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01140061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*